Onkologie. 2019:13(3):129-132 | DOI: 10.36290/xon.2019.025

Diffuse low grade gliomas – how it is to diagnose and treat effectively?

©tefan Reguli1, Jakub Cvek2, Radim Lipina1
1 Neurochirurgická klinika FN Ostrava
2 Onkologická klinika FN Ostrava

Diffuse low grade gliomas typically affect patients in working-age population. These tumors may pose high risk of growth accompanied with neurological deficit as well as malignant upgrade. Diagnosis and classification of these tumors changed significantly in last decade due to developing mutimodal magnetic resonance imaging and cytogenetic techniques. Genetic profile of tumor cells enables prognostic estimation and sensitivity to oncological therapy. Maximum safe surgical resection as upfront therapy is widely accepted. On the other hand, there are discussions and ongoing studies concerning radiotherapy and chemotherapy in treating algorithm of patients with low grade gliomas.

Keywords: low grade glioma, cytogenetics, radiotherapy, chemotherapy

Published: May 24, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Reguli ©, Cvek J, Lipina R. Diffuse low grade gliomas – how it is to diagnose and treat effectively? Onkologie. 2019;13(3):129-132. doi: 10.36290/xon.2019.025.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ostrom QT, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013. Neuro Oncol, 2016; 18(suppl_5): v1-v75. Go to original source... Go to PubMed...
    2. Wu J, et al. Comparison of Radiation Therapy Alone and Chemotherapy Alone for Low-Grade Gliomas without Surgical Resection. World Neurosurg, 2018. Go to original source...
    3. Cordova JS, et al. A systematic pipeline for the objective comparison of whole-brain spectroscopic MRI with histology in biopsy specimens from grade III glioma. Tomography, 2016; 2(2): 106-116. Go to original source... Go to PubMed...
    4. Nishio S, et al. Brain stem glioma: the role of a biopsy. Br J Neurosurg, 1991; 5(3): 265-73. Go to original source... Go to PubMed...
    5. Woodworth G, et al. Accuracy of frameless and frame-based image-guided stereotactic brain biopsy in the diagnosis of glioma: comparison of biopsy and open resection specimen. Neurol Res, 2005; 27(4): 358-62. Go to original source... Go to PubMed...
    6. Di N, et al. Can dynamic contrast-enhanced MRI evaluate VEGF expression in brain glioma? An MRI-guided stereotactic biopsy study. J Neuroradiol, 2018. Go to original source... Go to PubMed...
    7. Louis DN, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol, 2007; 114(2): 97-109. Go to original source... Go to PubMed...
    8. van den Bent MJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective. Acta Neuropathol, 2010; 120(3): 297-304. Go to original source... Go to PubMed...
    9. Olar A, et al. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol, 2015; 129(4): 585-96. Go to original source... Go to PubMed...
    10. Louis DN, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol, 2016; 131(6): 803-20. Go to original source... Go to PubMed...
    11. Pignatti F, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol, 2002; 20(8): 2076-84. Go to original source... Go to PubMed...
    12. Pallud J, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas. Neuro Oncol, 2013; 15(5): 595-606. Go to original source... Go to PubMed...
    13. Daniels TB, et al. Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51. Int J Radiat Oncol Biol Phys, 2011; 81(1): 218-24. Go to original source... Go to PubMed...
    14. Cancer Genome Atlas Research N, et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med, 2015; 372(26): 2481-98.
    15. Aghi MK, et al. The role of surgery in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline. J Neurooncol, 2015; 125(3): 503-30. Go to original source... Go to PubMed...
    16. Riva M, Bello L. Low-grade glioma management: a contemporary surgical approach. Curr Opin Oncol, 2014; 26(6): 615-21. Go to original source... Go to PubMed...
    17. Wang TJC, Mehta MP. Low-Grade Glioma Radiotherapy Treatment and Trials. Neurosurg Clin N Am, 2019; 30(1): 111-118. Go to original source... Go to PubMed...
    18. Shaw E, et al. Prospective randomized trial of low - versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol, 2002; 20(9): 2267-76. Go to original source... Go to PubMed...
    19. van den Bent MJ, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet, 2005; 366(9490): 985-90. Go to original source... Go to PubMed...
    20. Buckner JC, et al. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med, 2016; 374(14): 1344-55. Go to original source... Go to PubMed...
    21. Garcia CR, et al. Comprehensive evaluation of treatment and outcomes of low-grade diffuse gliomas. PLoS One, 2018; 13(9): e0203639. Go to original source... Go to PubMed...
    22. Sepulveda-Sanchez JM, et al. SEOM clinical guideline of diagnosis and management of low-grade glioma (2017). Clin Transl Oncol, 2018; 20(1): 3-15. Go to original source... Go to PubMed...
    23. Baumert BG, et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol; 2016. 17(11): 1521-1532. Go to original source... Go to PubMed...
    24. Hafazalla K, et al. Procarbazine, CCNU and vincristine (PCV) versus temozolomide chemotherapy for patients with low-grade glioma: a systematic review. Oncotarget, 2018; 9(72): 33623-33633. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.